Zobrazeno 1 - 10
of 518
pro vyhledávání: '"de Bono, JS"'
Autor:
Collins, DC, Sundar, R, Constantinidou, A, Dolling, D, Yap, TA, Popat, S, O'Brien, ME, Banerji, U, De Bono, JS, Lopez, JS, Tunariu, N, Minchom, A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1032::562a26896e5a55a0df516dbc974eb906
http://hdl.handle.net/10044/1/88252
http://hdl.handle.net/10044/1/88252
Publikováno v:
Clinical Pharmacology and Therapeutics
As a growing body of evidence demonstrates intertumoral and intratumoral heterogeneity and clonal evolution, both during carcinogenesis and also throughout treatment resulting in acquired drug resistance, the utility of blood-based assays or "liquid
Autor:
Heller, G, McCormack, R, Kheoh, T, Molina, A, Smith, MR, Dreicer, R, Saad, F, de Wit, Ronald, Aftab, DT, Hirmand, M, Limon-Carrera, A, Fizazi, K, Fleisher, M, de Bono, JS, Scher, HI
Publikováno v:
Journal of Clinical Oncology, 36(22), 2354-2355. American Society of Clinical Oncology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=narcis______::4dbd30068815e5ef97db2f2d5b81c5c2
https://pure.eur.nl/en/publications/85845653-b08d-4eba-a916-e95e976e65c3
https://pure.eur.nl/en/publications/85845653-b08d-4eba-a916-e95e976e65c3
Autor:
Ang, JE, Pal, A, Asad, YJ, Henley, AT, Valenti, M, Box, G, de haven Brandon, A, Revell, Victoria, Skene, Debra, Venturi, M, Rueger, R, Meresse, V, Eccles, SA, de Bono, JS, Kaye, SB, Workman, P, Banerji, U, Raynaud, FI
MAPK pathway activation is frequently observed in human malignancies, including melanoma, and is associated with sensitivity to MEK inhibition and changes in cellular metabolism. Using quantitative mass spectrometry-based metabolomics, we identified
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______305::68aab6af42953432ba15382da278000a
https://surrey.eprints-hosting.org/841474/
https://surrey.eprints-hosting.org/841474/
Autor:
Bianchini, D, Lorente, D, Rescigno, P, Zafeiriou, Z, Psychopaida, E, O'Sullivan, H, Alaras, M, Kolinsky, M, Sumanasuriya, S, Sousa Fontes M, Mateo, J, Perez Lopez R, Tunariu, N, Fotiadis, N, Kumar, P, Tree, A, Van As, N, Khoo, V, Parker, C, Eeles, R, Thompson, A, Dearnaley, D, de Bono, JS
Publikováno v:
Clinical Genitourinary Cancer
CLINICAL GENITOURINARY CANCER
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
CLINICAL GENITOURINARY CANCER
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Micro-Abstract We retrospectively evaluated the effect of locoregional treatment (LRT) on overall survival (OS) in 300 metastatic at diagnosis (M1) prostate cancer patients. LRT was associated in univariate and multivariate analysis with longer OS, w
Autor:
Papadatos-Pastos D, Roda D, De Miguel Luken MJ, Petruckevitch A, Jalil A, Capelan M, Michalarea V, Lima J, Diamantis N, Bhosle J, Molife LR, Banerji U, de Bono JS, Popat S, O'Brien MER, Yap TA
Publikováno v:
European journal of cancer (Oxford, England : 1990)
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::a1f85933511a33110121dafd490d9aea
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1508
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1508
Autor:
Beer, Tm, Armstrong, Aj, Rathkopf, De, Loriot, Y, Sternberg, Cn, Higano, Cs, Iversen, P, Bhattacharya, S, Carles, J, Chowdhury, S, Davis, Id, de Bono JS, Evans, Cp, Fizazi, K, Joshua, Am, Kim, Cs, Kimura, G, Mainwaring, P, Mansbach, H, Miller, K, Noonberg, Sb, Perabo, F, Phung, D, Saad, F, Scher, Hi, Taplin, Me, Venner, Pm, Tombal, B, Prevail, Investigators, Scagliotti, Giorgio Vittorio
Publikováno v:
The New England journal of medicine, vol 371, iss 5
New England Journal of Medicine, 371(5), 424-433. MASSACHUSETTS MEDICAL SOC
The New England Journal of Medicine, 371, 424-33
New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2014, 371 (5), pp.424-433. ⟨10.1056/NEJMoa1405095⟩
The New England Journal of Medicine, 371, 5, pp. 424-33
New England Journal of Medicine, 371(5), 424-433. MASSACHUSETTS MEDICAL SOC
The New England Journal of Medicine, 371, 424-33
New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2014, 371 (5), pp.424-433. ⟨10.1056/NEJMoa1405095⟩
The New England Journal of Medicine, 371, 5, pp. 424-33
Contains fulltext : 137932.pdf (Publisher’s version ) (Open Access) BACKGROUND: Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic castration-resistant prostate cancer in whom the disease has progresse
Publikováno v:
European Urology Focus
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
CONTEXT: Unprecedented development of therapeutics for prostate cancer in recent years has left clinicians with the challenge of adequately sequencing therapeutic agents to optimise patient benefit. No clear guidelines exist on optimal treatment sequ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::c06869c583cc03461f10b206d5736a3c
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=9829
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=9829
Autor:
Geuna E, Roda D, Rafii S, Jimenez B, Capelan M, Rihawi K, Montemurro F, Yap TA, Kaye SB, De Bono JS, Molife LR, Banerji U
Publikováno v:
BRITISH JOURNAL OF CANCER
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Background: PI3K-AKT-mTOR inhibitors (PAMi) are promising anticancer treatments. Hyperglycaemia is a mechanism-based toxicity of these agents and is becoming increasingly important with their use in larger numbers of patients. Methods: Retrospective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::bdb40600bddb3b0832fefd98a7ef52c0
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1506
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1506
Autor:
Rafii S, Roda D, Geuna E, Jimenez B, Rihawi K, Capelan M, Yap TA, Molife LR, Kaye SB, de Bono JS, Banerji U
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Purpose: Novel antitumor therapies against the PI3K-AKT-mTOR pathway are increasingly used to treat cancer, either as single agents or in combination with chemotherapy or other targeted therapies. Although these agents are not known to be myelosuppre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::15a814c909b0d8bb6fc67c348f3e1c6c
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1513
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1513